Longitudinal spectral flow cytometry profiling of 280+ samples to support a complex Phase I/II dose escalation trial.
The goal is to assess dose-dependent drug effects on AML blasts and immune cells using TokuKit fixation. Teiko’s 43-marker CyTOF panel processes ~500 samples. Results track 700+ subsets. The developer cut specimens from 3 to 1, saving ~$200 each, capturing responses within 30 minutes. Runtime is ongoing.
A $5B+ immunotherapy company aimed to assess drug impact on immune cell composition in 20 healthy volunteers across two doses and placebo in Phase 1. Teiko’s 42-marker panel analyzed 200 PBMC samples over 6.5 weeks. Results confirmed myeloid subset changes and significant T cell shifts, increasing resolution 17X to 858 subsets for indication selection.
A drug developer aimed to identify immune biomarkers and validate genomic data in 8 liver cancer patients using Teiko’s 43-marker CyTOF panel on 24 PBMC samples over 6 weeks. Results confirmed findings, detected dose-dependent changes, and delivered insights via a web dashboard, accelerating the clinical program by distinguishing drug effects.
A $3B+ AI drug developer in Phase 1 aimed to assess therapy’s impact on immune cell composition using a 42-marker CyTOF panel on 100 whole blood samples with TokuKits. Ongoing results show dose-dependent changes across 700+ subsets, with inter- and intra-run precision under 8%, saving $18K by replacing PBMC isolation.
